UK Stem Cell IPOs Defy Odds
This article was originally published in Start Up
Executive Summary
When ReNeuron Ltd. announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a sceptical laugh. But the subsequent IPO, although small, showed that even risky, pre-clinical bets can float--if they're priced low enough.
You may also be interested in...
Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
Stem Cells: US Controversy and UK Commitment
The debate over stem cells has produced a complex web of rules and regulations on both sides of the Atlantic. In the UK, the UK Stem Cell Foundation was established with the goal of attracting investors willing to support clinical research using stem cells, and to help translate basic research findings into clinically and commercially viable products. In the US, private firms have stepped into the gap created by a lack of federal research funding.